Bimodal Therapy for Prostatic Metastasis of Pulmonary Poorly Differentiated Adenocarcinoma: A Case Report

Altieri Vincenzo Maria1*, Lisanti Rocca Carmela1, Cavacece Fernando1, Saldutto Pietro1, Sollai Mario2, Colombo Piergiuseppe2, Manica Michele3, Verratti Vittore4, Altieri Barbara5 and Micheli Emanuele1

1Department of Urology, Humanitas Gavazzeni, Italy
2Department of Pathology, Humanitas Clinical and Research Center, Italy
3Department of Urology, ASST Papa Giovanni XXIII, Italy
4Department of Psychological, Health and Territorial Sciences, University “G. d’Annunzio" Chieti-Pescara, Italy
5Department of Internal Medicine I, University Hospital, University of Würzburg, Germany

^*Correspondance to: Altieri Vincenzo Maria 

 PDF  Full Text DOI: 10.25107/2474-1647.3406

Abstract

Secondary solid prostate neoplasms are rare conditions commonly diagnosed as incidental findings at autopsy. Melanoma and small cell carcinoma are the most common histotypes which metastasize at prostate. We report a rare case of prostatic metastasis of a poorly differentiated pulmonary adenocarcinoma, treated with bimodal therapy including surgery and systemic immunotherapy. A 68-year-old man with a history of a stage IB lung adenocarcinoma developed urinary symptoms which did not improve despite medical therapy. The patient underwent a Transurethral Prostatic Resection (TURP) followed by systemic administration of Nivolumab, a monoclonal antibody used to treat several sub-types of solid neoplasm including, melanoma, lung and kidney cancer. The patient remained asymptomatic and progression-free at 2 years after the start of immunotherapy.

Keywords

Prostate adenocarcinoma; Lung cancer; Metastasis; Immunohistochemistry; Transurethral resection of the prostate; Targeted therapy

Cite the article

Maria AV, Carmela LR, Fernando C, Pietro S, Mario S, Piergiuseppe C, et al. Bimodal Therapy for Prostatic Metastasis of Pulmonary Poorly Differentiated Adenocarcinoma: A Case Report. Clin Surg. 2022; 7: 3406..